A Form 4 filed on September 15, 2026 reports that Naimish Patel, a director of AgomAb Therapeutics NV (NASDAQ:AGMB), was granted stock options on September 11, 2026.

Key Highlights

  • Grant date: September 11, 2026, as reported by director Naimish Patel.
  • Options granted: 56,328 stock options (right to buy) covering 56,328 common shares were acquired with transaction code A.
  • Exercise price: $13.94 per share, reflecting conversion from EUR to USD at $1.1616 per EUR 1.00 as of September 10, 2026.
  • Expiration date: January 15, 2036, according to the filing.
  • Vesting schedule: 33% of the shares vest on September 11, 2027, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to continued service.
  • Post-transaction ownership: Patel beneficially owns 56,328 derivative securities directly following the reported transaction.

Naimish Patel Option Grant Details at AgomAb Therapeutics

According to the filing, Naimish Patel, identified as a director of AgomAb Therapeutics NV, received a grant of 56,328 stock options with a transaction date of September 11, 2026. The options carry an exercise price of $13.94 per share. The filing notes that this exercise price "reflects the conversion from EUR to USD at an exchange rate of $1.1616 per EUR 1.00 as of September 10, 2026." The price of the derivative security at acquisition is reported as $0.00.

The filing discloses that the options expire on January 15, 2036, and cover an equivalent number of common shares of AgomAb Therapeutics NV. The filing further notes that "the common shares may be represented by American Depositary Shares, each of which currently represents one common share." Ownership of the options is recorded as direct.

Regarding vesting, the filing states that "33% of the shares underlying this option shall vest on September 11, 2027, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date." Following the reported transaction, Patel's total beneficial ownership of derivative securities stands at 56,328 options. The form was signed by Ellen Lefever as attorney-in-fact on September 15, 2026. No non-derivative securities transactions were reported in Table I.

What Was Disclosed

The filing reports a single derivative securities transaction: the acquisition of 56,328 stock options by director Naimish Patel on September 11, 2026, at an exercise price of $13.94, expiring January 15, 2036, with a tiered vesting schedule tied to continued service.